
cholesterol (RR, 0.90; 95% CI, 0.87-0.93; P < .0001).141
The COMPASS Trial reported that the combination of
rivaroxaban (2.5 mg twice daily) and aspirin (100 mg
daily) was associated with a lower incidence of major
adverse cardiac and limb events than aspirin alone for
patients with stable peripheral